Detail

Paroxetine

Description

Name: Paroxetine
Type: small molecule
Groups: Array
Indication: Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.
Accession Number: DB00715 ( DB00715)
Description: Paroxetine hydrochloride and paroxetine mesylate belong to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a complete listing of side effects). Side effects generally occur during the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Paroxetine hydrochloride and mesylate are considered therapeutic alternatives rather than generic equivalents by the US Food and Drug Administration (FDA); both agents contain the same active moiety (i.e. paroxetine), but are formulated as different salt forms. Clinical studies establishing the efficacy of paroxetine in various conditions were performed using paroxetine hydrochloride. Since both agents contain the same active moiety, the clinical efficacy of both agents is thought to be similar. Paroxetine may be used to treat major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD) and premenstrual dysphoric disorder (PMDD). Paroxetine has the most evidence supporting its use for anxiety-related disorders of the SSRIs. It has the greatest anticholinergic activity of the agents in this class and compared to other SSRIs, paroxetine may cause greater weight gain, sexual dysfunction, sedation and constipation.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Act Paroxetinetablet10 mgoral14-03-2005Canada
Act Paroxetinetablet20 mgoral14-03-2005Canada
Act Paroxetinetablet30 mgoral14-03-2005Canada
Auro-paroxetinetablet10 mgoral24-07-2012Canada
Auro-paroxetinetablet20 mgoral24-07-2012Canada
Auro-paroxetinetablet30 mgoral24-07-2012Canada
Bio-paroxetinetablet10 mgoral01-01-1970Canada
Bio-paroxetinetablet20 mgoral01-01-1970Canada
Bio-paroxetinetablet30 mgoral01-01-1970Canada
Brisdellecapsule7.5 mg/1oral28-06-2013US
Dom-paroxetinetablet40 mgoral01-01-1970Canada
Dom-paroxetinetablet10 mgoral06-02-2004Canada
Dom-paroxetinetablet20 mgoral06-02-2004Canada
Dom-paroxetinetablet30 mgoral06-02-2004Canada
Ipg-paroxetinetablet10 mgoral01-01-1970Canada
Ipg-paroxetinetablet20 mgoral01-01-1970Canada
Ipg-paroxetinetablet30 mgoral01-01-1970Canada
Jamp-paroxetinetablet10 mgoral06-10-2011Canada
Jamp-paroxetinetablet20 mgoral24-10-2011Canada
Jamp-paroxetinetablet30 mgoral06-10-2011Canada
Mar-paroxetinetablet20 mgoral24-06-2014Canada
Mar-paroxetinetablet10 mgoral24-06-2014Canada
Mar-paroxetinetablet30 mgoral24-06-2014Canada
Mint-paroxetinetablet10 mgoral17-03-2014Canada
Mint-paroxetinetablet20 mgoral17-03-2014Canada
Mint-paroxetinetablet30 mgoral17-03-2014Canada
Mylan-paroxetinetablet10 mgoral08-10-2003Canada
Mylan-paroxetinetablet20 mgoral08-10-2003Canada
Mylan-paroxetinetablet30 mgoral08-10-2003Canada
Ntp-paroxetinetablet10 mgoral01-01-1970Canada
Ntp-paroxetinetablet20 mgoral01-01-1970Canada
Ntp-paroxetinetablet30 mgoral01-01-1970Canada
Nu-paroxetinetablet10 mgoral01-01-1970Canada
Nu-paroxetinetablet20 mgoral01-01-1970Canada
Nu-paroxetinetablet30 mgoral01-01-1970Canada
Paroxetinetablet10 mgoral26-06-2012Canada
Paroxetinetablet20 mgoral26-06-2012Canada
Paroxetinetablet30 mgoral26-06-2012Canada
Paroxetinetablet10 mgoral01-01-1970Canada
Paroxetinetablet20 mgoral01-01-1970Canada
Paroxetinetablet30 mgoral01-01-1970Canada
Paroxetinetablet10 mgoral26-02-200920-06-2014Canada
Paroxetinetablet20 mgoral26-02-200920-06-2014Canada
Paroxetinetablet30 mgoral26-02-200920-06-2014Canada
Paroxetinetablet10 mgoral22-10-2009Canada
Paroxetinetablet20 mgoral22-10-2009Canada
Paroxetinetablet30 mgoral22-10-2009Canada
Paroxetinetablet10 mgoral06-04-200425-06-2014Canada
Paroxetinetablet20 mgoral06-04-200425-06-2014Canada
Paroxetinetablet30 mgoral06-04-200425-06-2014Canada
Paroxetine-10tablet10 mgoral19-03-2004Canada
Paroxetine-20tablet20 mgoral19-03-2004Canada
Paroxetine-30tablet30 mgoral19-03-2004Canada
Paxiltablet, film coated20 mg/1oral18-09-2006US
Paxiltablet, film coated30 mg/1oral10-07-1996US
Paxil CRtablet, film coated, extended release12.5 mg/1oral09-04-2002US
Paxil CRtablet, film coated, extended release25 mg/1oral09-04-2002US
Paxil CRtablet, film coated, extended release12.5 mg/1oral09-04-2002US
Paxil CRtablet (extended-release)37.5 mgoral01-01-1970Canada
Paxil CRtablet (extended-release)12.5 mgoral05-01-2004Canada
Paxil CRtablet (extended-release)25 mgoral05-01-2004Canada
Paxil Tab 10mgtablet10 mgoral31-01-1997Canada
Paxil Tab 20mgtablet20 mgoral31-12-1993Canada
Paxil Tab 30mgtablet30 mgoral31-12-1993Canada
Paxilcr CRtablet, film coated, extended release12.5 mg/1oral06-07-2005US
Paxilcr CRtablet, film coated, extended release37.5 mg/1oral21-07-2005US
Paxilcr CRtablet, film coated, extended release25 mg/1oral16-05-2003US
Pexevatablet, film coated10 mg/1oral03-07-2003US
Pexevatablet, film coated20 mg/1oral03-07-2003US
Pexevatablet, film coated30 mg/1oral03-07-2003US
Pexevatablet, film coated40 mg/1oral03-07-2003US
PMS-paroxetinetablet10 mgoral29-10-2003Canada
PMS-paroxetinetablet20 mgoral29-10-2003Canada
PMS-paroxetinetablet30 mgoral29-10-2003Canada
PMS-paroxetinetablet40 mgoral03-05-2007Canada
Priva-paroxetinetablet10 mgoral01-01-1970Canada
Priva-paroxetinetablet20 mgoral01-01-1970Canada
Priva-paroxetinetablet30 mgoral01-01-1970Canada
Q-paroxetinetablet10 mgoral24-11-201121-08-2015Canada
Q-paroxetinetablet20 mgoral24-11-201121-08-2015Canada
Q-paroxetinetablet30 mgoral24-11-201121-08-2015Canada
Ratio-paroxetinetablet10 mgoral09-10-200319-09-2014Canada
Ratio-paroxetinetablet20 mgoral09-10-200319-09-2014Canada
Ratio-paroxetinetablet30 mgoral09-10-200319-09-2014Canada
Riva-paroxetinetablet10 mgoral16-02-2004Canada
Riva-paroxetinetablet20 mgoral16-02-2004Canada
Riva-paroxetinetablet30 mgoral16-02-2004Canada
Sandoz Paroxetinetablet10 mgoral27-07-2007Canada
Sandoz Paroxetinetablet20 mgoral27-07-2007Canada
Sandoz Paroxetinetablet30 mgoral27-07-2007Canada
Sandoz Paroxetinetablet20 mgoral21-09-200420-02-2012Canada
Sandoz Paroxetinetablet30 mgoral21-09-200420-02-2012Canada
Sandoz Paroxetine Tabletstablet10 mgoral31-10-2014Canada
Sandoz Paroxetine Tabletstablet20 mgoral31-10-2014Canada
Sandoz Paroxetine Tabletstablet30 mgoral31-10-2014Canada
Teva-paroxetinetablet10 mgoral16-01-2004Canada
Teva-paroxetinetablet20 mgoral16-01-2004Canada
Teva-paroxetinetablet30 mgoral16-01-2004Canada

Generic Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Apo-paroxetinetablet10 mgoral24-10-2003Canada
Apo-paroxetinetablet20 mgoral24-10-2003Canada
Apo-paroxetinetablet30 mgoral24-10-2003Canada
Paroxetinetablet, film coated40 mg/1oral18-02-2009US
Paroxetinetablet, film coated10 mg/1oral26-03-2013US
Paroxetinetablet, film coated10 mg/1oral13-04-2007US
Paroxetinetablet, film coated20 mg/1oral13-04-2007US
Paroxetinetablet, film coated30 mg/1oral13-04-2007US
Paroxetinetablet, film coated40 mg/1oral13-04-2007US
Paroxetinetablet, film coated10 mg/1oral13-04-2007US
Paroxetinetablet, film coated20 mg/1oral06-02-2014US
Paroxetinetablet, film coated20 mg/1oral13-04-2007US
Paroxetinetablet, film coated10 mg/1oral07-06-2010US
Paroxetinetablet, film coated20 mg/1oral07-06-2010US
Paroxetinetablet, film coated20 mg/1oral15-10-2008US
Paroxetinetablet, film coated20 mg/1oral13-04-2007US
Paroxetinetablet, film coated10 mg/1oral07-04-2004US
Paroxetinetablet, film coated20 mg/1oral13-04-2007US
Paroxetinetablet, film coated30 mg/1oral01-01-2015US
Paroxetinetablet, film coated20 mg/1oral08-09-2003US
Paroxetinetablet, film coated20 mg/1oral03-10-2005US
Paroxetinetablet, film coated10 mg/1oral03-10-2014US
Paroxetinetablet10 mg/1oral18-04-2011US
Paroxetinetablet, film coated10 mg/1oral07-11-2005US
Paroxetinetablet, film coated20 mg/1oral03-10-2005US
Paroxetinetablet, film coated30 mg/1oral02-11-2005US
Paroxetinetablet, film coated40 mg/1oral02-11-2005US
Paroxetinetablet, film coated20 mg/1oral08-09-2003US
Paroxetinetablet, film coated30 mg/1oral08-09-2003US
Paroxetinetablet, film coated10 mg/1oral08-09-2003US
Paroxetinetablet, film coated40 mg/1oral08-09-2003US
Paroxetinetablet, film coated20 mg/1oral08-09-2003US
Paroxetinetablet, film coated10 mg/1oral08-09-2003US
Paroxetinetablet, film coated10 mg/1oral17-08-2004US
Paroxetinetablet, film coated20 mg/1oral01-11-2014US
Paroxetinetablet, film coated10 mg/1oral11-08-2010US
Paroxetinetablet, film coated20 mg/1oral11-08-2010US
Paroxetinetablet, film coated30 mg/1oral11-08-2010US
Paroxetinetablet, film coated40 mg/1oral11-08-2010US
Paroxetinetablet, film coated40 mg/1oral06-02-2014US
Paroxetinetablet, film coated10 mg/1oral04-06-2013US
Paroxetinetablet, film coated10 mg/1oral08-09-2003US
Paroxetinetablet, film coated20 mg/1oral08-09-2003US
Paroxetinetablet, film coated20 mg/1oral13-04-2007US
Paroxetinetablet, film coated10 mg/1oral13-04-2007US
Paroxetinetablet, film coated20 mg/1oral13-04-2007US
Paroxetinetablet10 mg/1oral01-07-2009US
Paroxetinetablet20 mg/1oral01-07-2009US
Paroxetinetablet20 mg/1oral01-07-2009US
Paroxetinetablet30 mg/1oral01-07-2009US
Paroxetinetablet, film coated10 mg/1oral07-06-2010US
Paroxetinetablet30 mg/1oral01-07-2009US
Paroxetinetablet, film coated20 mg/1oral07-06-2010US
Paroxetinetablet40 mg/1oral01-07-2009US
Paroxetinetablet, film coated30 mg/1oral07-06-2010US
Paroxetinetablet, film coated40 mg/1oral07-06-2010US
Paroxetinetablet40 mg/1oral01-07-2009US
Paroxetinetablet, film coated20 mg/1oral14-02-2004US
Paroxetinetablet, film coated10 mg/1oral13-04-2007US
Paroxetinetablet, film coated30 mg/1oral13-04-2007US
Paroxetinetablet, film coated40 mg/1oral13-04-2007US
Paroxetinetablet, film coated20 mg/1oral03-03-2015US
Paroxetinetablet, film coated10 mg/1oral08-09-2003US
Paroxetinetablet, film coated10 mg/1oral14-02-2004US
Paroxetinetablet, film coated40 mg/1oral13-04-2007US
Paroxetinetablet, film coated10 mg/1oral01-01-2014US
Paroxetinetablet, film coated10 mg/1oral08-09-2003US
Paroxetinetablet, film coated20 mg/1oral08-09-2003US
Paroxetinetablet, film coated30 mg/1oral08-09-2003US
Paroxetinetablet, film coated40 mg/1oral08-09-2003US
Paroxetine Hydrochloridetablet20 mg/1oral11-07-2011US
Paroxetine Hydrochloridetablet, film coated, extended release12.5 mg/1oral25-10-2010US
Paroxetine Hydrochloridetablet20 mg/1oral21-07-2011US
Paroxetine Hydrochloridetablet20 mg/1oral29-03-2011US
Paroxetine Hydrochloridetablet, film coated, extended release25 mg/1oral23-05-2008US
Paroxetine Hydrochloridetablet10 mg/1oral03-11-2011US
Paroxetine Hydrochloridetablet40 mg/1oral07-06-2011US
Paroxetine Hydrochloridetablet30 mg/1oral16-06-2011US
Paroxetine Hydrochloridetablet10 mg/1oral17-06-2011US
Paroxetine Hydrochloride Anhydroustablet, film coated20 mg/1oral01-01-2014US

Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Paxil CRParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Paxil CRParoxetine
Paxil CRParoxetine
ParoxetineParoxetine
Paroxetine HydrochlorideParoxetine
Paroxetine HydrochlorideParoxetine
Paroxetine HydrochlorideParoxetine
Paroxetine HydrochlorideParoxetine
Paroxetine HydrochlorideParoxetine
Paroxetine HydrochlorideParoxetine
Paroxetine HydrochlorideParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Paroxetine HydrochlorideParoxetine
PaxilParoxetine
PaxilParoxetine
Paxilcr CRParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Paxilcr CRParoxetine
Paxilcr CRParoxetine
Paroxetine HydrochlorideParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Paroxetine Hydrochloride AnhydrousParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
PexevaParoxetine
PexevaParoxetine
PexevaParoxetine
PexevaParoxetine
BrisdelleParoxetine
Paxil Tab 30mgParoxetine
Paxil Tab 20mgParoxetine
Paxil Tab 10mgParoxetine
Apo-paroxetineParoxetine
Apo-paroxetineParoxetine
Apo-paroxetineParoxetine
PMS-paroxetineParoxetine
PMS-paroxetineParoxetine
PMS-paroxetineParoxetine
Mylan-paroxetineParoxetine
Mylan-paroxetineParoxetine
Mylan-paroxetineParoxetine
Dom-paroxetineParoxetine
Dom-paroxetineParoxetine
Dom-paroxetineParoxetine
Paxil CRParoxetine
Paxil CRParoxetine
Teva-paroxetineParoxetine
Teva-paroxetineParoxetine
Teva-paroxetineParoxetine
Riva-paroxetineParoxetine
Riva-paroxetineParoxetine
Riva-paroxetineParoxetine
Paroxetine-10Paroxetine
Paroxetine-20Paroxetine
Paroxetine-30Paroxetine
Act ParoxetineParoxetine
Act ParoxetineParoxetine
Act ParoxetineParoxetine
Sandoz ParoxetineParoxetine
Sandoz ParoxetineParoxetine
Sandoz ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
PMS-paroxetineParoxetine
Auro-paroxetineParoxetine
Auro-paroxetineParoxetine
Auro-paroxetineParoxetine
Mar-paroxetineParoxetine
Mar-paroxetineParoxetine
Mar-paroxetineParoxetine
Mint-paroxetineParoxetine
Mint-paroxetineParoxetine
Mint-paroxetineParoxetine
Sandoz Paroxetine TabletsParoxetine
Sandoz Paroxetine TabletsParoxetine
Sandoz Paroxetine TabletsParoxetine
Ratio-paroxetineParoxetine
Ratio-paroxetineParoxetine
Ratio-paroxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Sandoz ParoxetineParoxetine
Sandoz ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Q-paroxetineParoxetine
Q-paroxetineParoxetine
Q-paroxetineParoxetine
Nu-paroxetineParoxetine
Nu-paroxetineParoxetine
Nu-paroxetineParoxetine
Paxil CRParoxetine
Dom-paroxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
Ntp-paroxetineParoxetine
Ntp-paroxetineParoxetine
Ntp-paroxetineParoxetine
Ipg-paroxetineParoxetine
Ipg-paroxetineParoxetine
Ipg-paroxetineParoxetine
Priva-paroxetineParoxetine
Priva-paroxetineParoxetine
Priva-paroxetineParoxetine
Bio-paroxetineParoxetine
Bio-paroxetineParoxetine
Bio-paroxetineParoxetine
Jamp-paroxetineParoxetine
Jamp-paroxetineParoxetine
Jamp-paroxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine
ParoxetineParoxetine

Categories
  • Serotonin Uptake Inhibitors
  • Antidepressive Agents

Pharmacology

Indication: Labeled indications include: major depressive disorder (MDD), panic disorder with or without agoraphobia, obsessive-compulsive disorder (OCD), social anxiety disorder (social phobia), generalized anxiety disorder (GAD), post-traumatic stress disorder (PTSD), and premenstrual dysphoric disorder (PMDD). Unlabeled indications include: eating disorders, impulse control disorders, vasomotor symptoms of menopause, obsessive-compulsive disorder (OCD) in children, and mild dementia-associated agitation in nonpsychotic individuals. Brisdelle, which consists of paroxetine mesylate is indicated for the treatment of moderate to severe vasomotor symptoms (like hot flashes) associated with menopause.
Pharmacodynamics: Not Available
Mechanism of action: Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown.
Absorption: Paroxetine hydrochloride is slowly, but completely absorbed following oral administration. Paroxetine mesylate salt is also completely absorbed after oral dosing. The oral bioavailability appears to be low due to extensive first-pass metabolism. Paroxetine hydrochloride oral tablets and suspension are reportedly bioequivalent. Absorption of either salt form is not substantially affected by food. Peak concentrations of Brisbelle (mesylate salt) were reached at 6 hours (3 to 8 hours range). Steady state Cmax was 13.10 ng/mL. The steady state AUC (0-last) was 237 hr*ng/mL. Paroxetine mesylate generally follows non-linear pharmacokinetics because CYP2D6, the enzyme that is part responisible for paroxetine metabolism, is readily saturable.
Volume of distribution:
    3.1-28 L/kg observed in animal studies. Paroxetine distributes throughout the body, including the central nervous system, with only 1% remaining in the plasma.

Protein binding: ~ 95% bound to plasma proteins.
Metabolism: Not Available
Route of elimination: Approximately 64% of a 30 mg oral solution of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites. Approximately 36% of the dose was excreted in the feces (via bile), mostly as metabolites and less than 1% as parent compound.
Half life: 21-24 hours
Clearance: Not Available
Toxicity: LD50=500mg/kg (orally in mice). Symptoms of overdose include: coma, dizziness, drowsiness, facial flushing, nausea, sweating, tremor, vomiting. Side effects include: nervous system effects such as asthenia, somnolence, dizziness, insomnia, tremor, and nervousness; GI effects such as nausea, decreased appetite, constipation, diarrhea, and dry mouth; impotence, ejaculatory dysfunction (principally ejaculatory delay), and other male genital disorders; female genital disorders (principally anorgasmia or difficulty reaching climax/orgasm); and sweating. Discontinuation syndrome may occur with abrupt withdrawal. Symptoms of discontinuation syndrome include flu-like symptoms, insomnia, nausea, imbalance, sensory changes, and hyperactivity.
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Glaxosmithkline
  • Apotex inc
  • Mylan pharmaceuticals inc
  • Actavis elizabeth llc
  • Alphapharm pty ltd
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Noven therapeutics llc

Packagers:
Dosage forms
FormRouteStrength
Capsuleoral7.5 mg/1
Tabletoral10 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral20 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral40 mg/1
Tabletoral20 mg/1
Tabletoral30 mg/1
Tabletoral40 mg/1
Tablet (extended-release)oral12.5 mg
Tablet (extended-release)oral25 mg
Tablet (extended-release)oral37.5 mg
Tablet, film coated, extended releaseoral12.5 mg/1
Tablet, film coated, extended releaseoral25 mg/1
Tabletoral10 mg
Tabletoral20 mg
Tabletoral30 mg
Tablet, film coated, extended releaseoral37.5 mg/1
Tabletoral40 mg

Prices
Unit descriptionCostUnit
Apo-Paroxetine 20 mg Tablet$1.05tablet
Co Paroxetine 20 mg Tablet$1.05tablet
Mylan-Paroxetine 20 mg Tablet$1.05tablet
Novo-Paroxetine 20 mg Tablet$1.05tablet
Phl-Paroxetine 20 mg Tablet$1.05tablet
Pms-Paroxetine 20 mg Tablet$1.05tablet
Ratio-Paroxetine 20 mg Tablet$1.05tablet
Sandoz Paroxetine 20 mg Tablet$1.05tablet
Apo-Paroxetine 30 mg Tablet$1.12tablet
Co Paroxetine 30 mg Tablet$1.12tablet
Mylan-Paroxetine 30 mg Tablet$1.12tablet
Novo-Paroxetine 30 mg Tablet$1.12tablet
Phl-Paroxetine 30 mg Tablet$1.12tablet
Pms-Paroxetine 30 mg Tablet$1.12tablet
Ratio-Paroxetine 30 mg Tablet$1.12tablet
Sandoz Paroxetine 30 mg Tablet$1.12tablet
Paxil 20 mg Tablet$2.03tablet
Pms-Paroxetine 40 mg Tablet$2.1tablet
Paxil 30 mg Tablet$2.16tablet
Paroxetine hcl 10 mg tablet$2.58tablet
Paroxetine hcl 20 mg tablet$2.7tablet
Paroxetine hcl 30 mg tablet$2.78tablet
Paroxetine hcl 40 mg tablet$2.93tablet
PARoxetine HCl 12.5 mg 24 Hour tablet$3.76tablet
Paxil 10 mg tablet$3.91tablet
PARoxetine HCl 25 mg 24 Hour tablet$3.93tablet
Paxil cr 12.5 mg tablet$4.02tablet
PARoxetine HCl 37.5 mg 24 Hour tablet$4.04tablet
Paxil 20 mg tablet$4.16tablet
Paxil CR 12.5 mg 24 Hour tablet$4.18tablet
Paxil 30 mg tablet$4.2tablet
Paxil cr 25 mg tablet$4.2tablet
Paxil cr 37.5 mg tablet$4.32tablet
Paxil CR 25 mg 24 Hour tablet$4.37tablet
Paxil 40 mg tablet$4.44tablet
Paxil CR 37.5 mg 24 Hour tablet$4.5tablet
Pexeva 10 mg tablet$5.6tablet
Pexeva 20 mg tablet$5.84tablet
Pexeva 30 mg tablet$6.11tablet
Pexeva 40 mg tablet$6.29tablet
Paxil 30 10 mg tablet Bottle$121.87bottle
Paxil 30 30 mg tablet Bottle$131.0bottle
Paxil 30 40 mg tablet Bottle$138.39bottle
Paxil 10 mg/5ml Suspension$0.85ml

Patents
CountryPatent NumberApprovedExpires (estimated)
6703408United States2002-10-212022-10-21
5789449United States1992-07-062009-07-06
2445678Canada2009-11-242016-07-19
2168829Canada1997-12-162016-02-05

Interactions

Drug Interactions
DrugInteraction
AbciximabParoxetine may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Paroxetine can be increased when it is combined with Abiraterone.
AcarboseParoxetine may increase the hypoglycemic activities of Acarbose.
AcenocoumarolParoxetine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acepromazine.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Paroxetine.
AcetophenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Acetophenazine.
Acetylsalicylic acidParoxetine may increase the antiplatelet activities of Acetylsalicylic acid.
AlbiglutideParoxetine may increase the hypoglycemic activities of Albiglutide.
AlfentanilAlfentanil may increase the serotonergic activities of Paroxetine.
AlogliptinParoxetine may increase the hypoglycemic activities of Alogliptin.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Paroxetine.
AlteplaseParoxetine may increase the anticoagulant activities of Alteplase.
AmisulprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Paroxetine.
AmoxapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amoxapine.
AnistreplaseParoxetine may increase the anticoagulant activities of Anistreplase.
ApixabanThe risk or severity of adverse effects can be increased when Paroxetine is combined with Apixaban.
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Paroxetine.
AripiprazoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.
AsenapineParoxetine may increase the QTc-prolonging activities of Asenapine.
AtomoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Paroxetine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Paroxetine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Paroxetine.
BendroflumethiazideParoxetine may increase the activities of Bendroflumethiazide.
BenzquinamideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Benzquinamide.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Paroxetine.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Paroxetine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Paroxetine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Paroxetine.
BuprenorphineBuprenorphine may increase the serotonergic activities of Paroxetine.
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.
BuspironeBuspirone may increase the serotonergic activities of Paroxetine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Paroxetine.
ButorphanolButorphanol may increase the serotonergic activities of Paroxetine.
CaffeineThe risk or severity of adverse effects can be increased when Caffeine is combined with Paroxetine.
CanagliflozinParoxetine may increase the hypoglycemic activities of Canagliflozin.
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Paroxetine.
CarbidopaThe risk or severity of adverse effects can be increased when Carbidopa is combined with Paroxetine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Paroxetine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.
CarphenazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Carphenazine.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Paroxetine.
CelecoxibParoxetine may increase the antiplatelet activities of Celecoxib.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlormezanone.
ChlorothiazideParoxetine may increase the activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Paroxetine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Paroxetine.
ChlorpropamideParoxetine may increase the hypoglycemic activities of Chlorpropamide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlorprothixene.
ChlorthalidoneParoxetine may increase the activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Paroxetine.
CimetidineThe metabolism of Paroxetine can be decreased when combined with Cimetidine.
CitalopramParoxetine may increase the QTc-prolonging activities of Citalopram.
Citric AcidParoxetine may increase the anticoagulant activities of Citric Acid.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Paroxetine.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Paroxetine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Paroxetine.
ClofedanolThe risk or severity of adverse effects can be increased when Clofedanol is combined with Paroxetine.
ClomipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Paroxetine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Paroxetine.
ClozapineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Clozapine.
CobicistatThe serum concentration of Paroxetine can be increased when it is combined with Cobicistat.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Paroxetine.
CollagenaseThe risk or severity of adverse effects can be increased when Paroxetine is combined with Collagenase.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Paroxetine.
CyproheptadineThe therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.
Dabigatran etexilateParoxetine may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinParoxetine may increase the anticoagulant activities of Dalteparin.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.
DapagliflozinParoxetine may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.
DarunavirThe serum concentration of Paroxetine can be decreased when it is combined with Darunavir.
DasatinibDasatinib may increase the anticoagulant activities of Paroxetine.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Paroxetine is combined with Deoxycholic Acid.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine.
DesipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Paroxetine.
DesmopressinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Desmopressin.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.
Dexchlorpheniramine maleateThe risk or severity of adverse effects can be increased when Dexchlorpheniramine maleate is combined with Paroxetine.
DextromethorphanParoxetine may increase the serotonergic activities of Dextromethorphan.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Paroxetine.
DiclofenacParoxetine may increase the antiplatelet activities of Diclofenac.
DicoumarolParoxetine may increase the anticoagulant activities of Dicoumarol.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Paroxetine.
DiflunisalParoxetine may increase the antiplatelet activities of Diflunisal.
DihydrocodeineParoxetine may increase the antiplatelet activities of Dihydrocodeine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Paroxetine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Paroxetine.
DisopyramideParoxetine may increase the hypoglycemic activities of Disopyramide.
DofetilideParoxetine may increase the QTc-prolonging activities of Dofetilide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Paroxetine.
DoxepinThe risk or severity of adverse effects can be increased when Paroxetine is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Paroxetine.
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Paroxetine.
DulaglutideParoxetine may increase the hypoglycemic activities of Dulaglutide.
DuloxetineDuloxetine may increase the serotonergic activities of Paroxetine.
Edetic AcidParoxetine may increase the anticoagulant activities of Edetic Acid.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Paroxetine.
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Paroxetine.
EmpagliflozinParoxetine may increase the hypoglycemic activities of Empagliflozin.
EnoxaparinParoxetine may increase the anticoagulant activities of Enoxaparin.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.
ErythromycinParoxetine may increase the hypoglycemic activities of Erythromycin.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Paroxetine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Paroxetine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Paroxetine.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Paroxetine.
Ethyl biscoumacetateParoxetine may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacParoxetine may increase the antiplatelet activities of Etodolac.
ExenatideParoxetine may increase the hypoglycemic activities of Exenatide.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Paroxetine.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.
FencamfamineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fencamfamine.
FenoprofenParoxetine may increase the antiplatelet activities of Fenoprofen.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Paroxetine.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Paroxetine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Paroxetine.
FloctafenineParoxetine may increase the antiplatelet activities of Floctafenine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Paroxetine.
FluoxetineThe metabolism of Paroxetine can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Paroxetine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.
FlurbiprofenParoxetine may increase the antiplatelet activities of Flurbiprofen.
FluspirileneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Paroxetine.
FluvoxamineThe metabolism of Fluvoxamine can be decreased when combined with Paroxetine.
Fondaparinux sodiumParoxetine may increase the anticoagulant activities of Fondaparinux sodium.
FosamprenavirThe serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of the active metabolites of Fosaprepitant can be reduced when Fosaprepitant is used in combination with Paroxetine resulting in a loss in efficacy.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Paroxetine.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Paroxetine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Paroxetine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Paroxetine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Paroxetine.
GliclazideParoxetine may increase the hypoglycemic activities of Gliclazide.
GlimepirideParoxetine may increase the hypoglycemic activities of Glimepiride.
GlipizideParoxetine may increase the hypoglycemic activities of Glipizide.
GlucosamineGlucosamine may increase the antiplatelet activities of Paroxetine.
GlyburideParoxetine may increase the hypoglycemic activities of Glyburide.
GoserelinParoxetine may increase the QTc-prolonging activities of Goserelin.
GranisetronGranisetron may increase the serotonergic activities of Paroxetine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paroxetine.
HeparinParoxetine may increase the anticoagulant activities of Heparin.
HydrochlorothiazideParoxetine may increase the activities of Hydrochlorothiazide.
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Paroxetine resulting in a loss in efficacy.
HydromorphoneHydromorphone may increase the serotonergic activities of Paroxetine.
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine.
IbritumomabThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ibritumomab.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Paroxetine.
IbuprofenParoxetine may increase the antiplatelet activities of Ibuprofen.
IcosapentParoxetine may increase the antiplatelet activities of Icosapent.
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Paroxetine.
ImipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Imipramine.
IndapamideParoxetine may increase the activities of Indapamide.
IndomethacinParoxetine may increase the antiplatelet activities of Indomethacin.
inhaled insulinParoxetine may increase the hypoglycemic activities of inhaled insulin.
Insulin AspartParoxetine may increase the hypoglycemic activities of Insulin Aspart.
Insulin degludecParoxetine may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirParoxetine may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineParoxetine may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineParoxetine may increase the hypoglycemic activities of Insulin Glulisine.
Insulin LisproParoxetine may increase the hypoglycemic activities of Insulin Lispro.
Insulin RegularParoxetine may increase the hypoglycemic activities of Insulin Regular.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Paroxetine.
Ioflupane I 123Paroxetine may decrease effectiveness of Ioflupane I 123 as a diagnostic agent.
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Paroxetine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Paroxetine.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Paroxetine.
KetoprofenParoxetine may increase the antiplatelet activities of Ketoprofen.
KetorolacParoxetine may increase the antiplatelet activities of Ketorolac.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Paroxetine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.
LanreotideParoxetine may increase the hypoglycemic activities of Lanreotide.
LeuprolideParoxetine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Paroxetine.
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Paroxetine.
LevorphanolLevorphanol may increase the serotonergic activities of Paroxetine.
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.
LimaprostLimaprost may increase the antiplatelet activities of Paroxetine.
LinezolidLinezolid may increase the serotonergic activities of Paroxetine.
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Paroxetine.
LiraglutideParoxetine may increase the hypoglycemic activities of Liraglutide.
LithiumLithium may increase the serotonergic activities of Paroxetine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Paroxetine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.
MecaserminParoxetine may increase the hypoglycemic activities of Mecasermin.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Paroxetine.
Mefenamic acidParoxetine may increase the antiplatelet activities of Mefenamic acid.
MeloxicamParoxetine may increase the antiplatelet activities of Meloxicam.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.
MequitazineThe serum concentration of Mequitazine can be increased when it is combined with Paroxetine.
MesoridazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.
MetforminParoxetine may increase the hypoglycemic activities of Metformin.
MethadoneThe metabolism of Methadone can be decreased when combined with Paroxetine.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Paroxetine.
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.
MethyclothiazideParoxetine may increase the activities of Methyclothiazide.
Methylene blueParoxetine may increase the serotonergic activities of Methylene blue.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.
MetolazoneParoxetine may increase the activities of Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.
MexiletineThe metabolism of Mexiletine can be decreased when combined with Paroxetine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Paroxetine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Paroxetine.
MiglitolParoxetine may increase the hypoglycemic activities of Miglitol.
MoclobemideMoclobemide may increase the serotonergic activities of Paroxetine.
MolindoneThe risk or severity of adverse effects can be increased when Paroxetine is combined with Molindone.
MorphineMorphine may increase the serotonergic activities of Paroxetine.
NabumetoneParoxetine may increase the antiplatelet activities of Nabumetone.
NadololParoxetine may increase the activities of Nadolol.
NalbuphineNalbuphine may increase the serotonergic activities of Paroxetine.
NaproxenParoxetine may increase the antiplatelet activities of Naproxen.
NateglinideParoxetine may increase the hypoglycemic activities of Nateglinide.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.
NefazodoneParoxetine may increase the serotonergic activities of Nefazodone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Paroxetine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Paroxetine.
NortriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Nortriptyline.
ObinutuzumabThe risk or severity of adverse effects can be increased when Paroxetine is combined with Obinutuzumab.
OctreotideParoxetine may increase the hypoglycemic activities of Octreotide.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Paroxetine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paroxetine.
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Paroxetine.
OndansetronThe risk or severity of adverse effects can be increased when Paroxetine is combined with Ondansetron.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Paroxetine.
OxaprozinParoxetine may increase the antiplatelet activities of Oxaprozin.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.
OxycodoneOxycodone may increase the serotonergic activities of Paroxetine.
OxymorphoneOxymorphone may increase the serotonergic activities of Paroxetine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Paroxetine.
PanobinostatThe serum concentration of Paroxetine can be increased when it is combined with Panobinostat.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Paroxetine.
PasireotideParoxetine may increase the hypoglycemic activities of Pasireotide.
Peginterferon alfa-2bThe serum concentration of Paroxetine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineParoxetine may increase the hypoglycemic activities of Pentamidine.
PentazocinePentazocine may increase the serotonergic activities of Paroxetine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Paroxetine.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Paroxetine.
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Paroxetine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Paroxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Paroxetine.
PhenelzinePhenelzine may increase the serotonergic activities of Paroxetine.
PhenindioneParoxetine may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Paroxetine.
PhenprocoumonParoxetine may increase the anticoagulant activities of Phenprocoumon.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Paroxetine.
PimozideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Paroxetine.
PioglitazoneParoxetine may increase the hypoglycemic activities of Pioglitazone.
PiperacetazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Piperacetazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Paroxetine.
PiroxicamParoxetine may increase the antiplatelet activities of Piroxicam.
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Paroxetine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.
PramlintideParoxetine may increase the hypoglycemic activities of Pramlintide.
PravastatinThe risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Paroxetine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Paroxetine.
ProcarbazineProcarbazine may increase the serotonergic activities of Paroxetine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paroxetine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Paroxetine.
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Paroxetine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Paroxetine.
ProtriptylineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Paroxetine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Paroxetine.
QuinineParoxetine may increase the hypoglycemic activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.
RasagilineRasagiline may increase the serotonergic activities of Paroxetine.
RemifentanilRemifentanil may increase the serotonergic activities of Paroxetine.
RemoxiprideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Remoxipride.
RepaglinideParoxetine may increase the hypoglycemic activities of Repaglinide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.
ReteplaseParoxetine may increase the anticoagulant activities of Reteplase.
RidogrelParoxetine may increase the anticoagulant activities of Ridogrel.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Paroxetine.
RitonavirThe metabolism of Paroxetine can be decreased when combined with Ritonavir.
RivaroxabanParoxetine may increase the anticoagulant activities of Rivaroxaban.
RosiglitazoneParoxetine may increase the hypoglycemic activities of Rosiglitazone.
Salicylate-sodiumThe risk or severity of adverse effects can be increased when Paroxetine is combined with Salicylate-sodium.
SaxagliptinParoxetine may increase the hypoglycemic activities of Saxagliptin.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Paroxetine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.
SelegilineSelegiline may increase the serotonergic activities of Paroxetine.
SertindoleThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sertindole.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Paroxetine.
SitagliptinParoxetine may increase the hypoglycemic activities of Sitagliptin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Paroxetine.
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Paroxetine.
StreptokinaseParoxetine may increase the anticoagulant activities of Streptokinase.
SufentanilSufentanil may increase the serotonergic activities of Paroxetine.
SulfadiazineParoxetine may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleParoxetine may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleParoxetine may increase the hypoglycemic activities of Sulfisoxazole.
SulindacParoxetine may increase the antiplatelet activities of Sulindac.
SulodexideParoxetine may increase the anticoagulant activities of Sulodexide.
SulpirideThe risk or severity of adverse effects can be increased when Paroxetine is combined with Sulpiride.
SunitinibParoxetine may increase the hypoglycemic activities of Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Paroxetine.
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Paroxetine resulting in a loss in efficacy.
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Paroxetine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Paroxetine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.
TenecteplaseParoxetine may increase the anticoagulant activities of Tenecteplase.
TetrabenazineThe serum concentration of Tetrabenazine can be increased when it is combined with Paroxetine.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Paroxetine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Paroxetine.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Paroxetine.
Thyroid extractThe therapeutic efficacy of Thyroid extract can be decreased when used in combination with Paroxetine.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.
Tiaprofenic acidParoxetine may increase the antiplatelet activities of Tiaprofenic acid.
TiclopidineThe metabolism of Paroxetine can be decreased when combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Paroxetine.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Paroxetine.
TolazamideParoxetine may increase the hypoglycemic activities of Tolazamide.
TolbutamideParoxetine may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.
TolmetinParoxetine may increase the antiplatelet activities of Tolmetin.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Paroxetine.
TositumomabThe risk or severity of adverse effects can be increased when Paroxetine is combined with Tositumomab.
TramadolParoxetine may increase the neuroexcitatory activities of Tramadol.
TranylcypromineTranylcypromine may increase the serotonergic activities of Paroxetine.
TrazodoneParoxetine may increase the serotonergic activities of Trazodone.
TreprostinilParoxetine may increase the anticoagulant activities of Treprostinil.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.
TrichlormethiazideParoxetine may increase the activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Paroxetine.
TriflupromazineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Triflupromazine.
TrimethoprimParoxetine may increase the hypoglycemic activities of Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Paroxetine.
UrokinaseParoxetine may increase the anticoagulant activities of Urokinase.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.
Vitamin EVitamin E may increase the antiplatelet activities of Paroxetine.
VortioxetineThe serum concentration of Vortioxetine can be increased when it is combined with Paroxetine.
WarfarinParoxetine may increase the anticoagulant activities of Warfarin.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Paroxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Paroxetine.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Paroxetine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Paroxetine.

Food Interactions:
  • Take without regard to meals. Avoid alcohol.

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Acetals
  • Alkyl aryl ethers
  • Aralkylamines
  • Aryl fluorides
  • Azacyclic compounds
  • Benzodioxoles
  • Dialkylamines
  • Fluorobenzenes
  • Hydrocarbon derivatives
  • Organofluorides
  • Oxacyclic compounds

substituent:
  • Acetal
  • Alkyl aryl ether
  • Amine
  • Aralkylamine
  • Aromatic heteropolycyclic compound
  • Aryl fluoride
  • Aryl halide
  • Azacycle
  • Benzenoid
  • Benzodioxole
  • Ether
  • Fluorobenzene
  • Halobenzene
  • Hydrocarbon derivative
  • Monocyclic benzene moiety
  • Organofluoride
  • Organohalogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Oxacycle
  • Phenylpiperidine
  • Secondary aliphatic amine
  • Secondary amine

References

Synthesis Reference: Charles M. Zepp, Yun Gao, Donald L. Heefner, "Method of preparing optically pure precursors of paroxetine." U.S. Patent US5258517, issued January, 1976.
General Reference: # Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16272179 # Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999 Aug;175:120-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10627793 # Yonkers KA, Gullion C, Williams A, Novak K, Rush AJ: Paroxetine as a treatment for premenstrual dysphoric disorder. J Clin Psychopharmacol. 1996 Feb;16(1):3-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8834412 # Waldinger MD, Hengeveld MW, Zwinderman AH, Olivier B: Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol. 1998 Aug;18(4):274-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9690692 # Waldinger MD, Zwinderman AH, Olivier B: SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol. 2001 Dec;21(6):556-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11763001
External Links:
ResourceLink
RxListhttp://www.rxlist.com/cgi/generic/parox.htm
Drugs.comhttp://www.drugs.com/paroxetine.html

ATC Codes:
  • Array

AHFS Codes:
  • 28:16.04.20

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?